Mind Medicine Inc.

Robert Barrow
Chief Executive Officer and Board Director

Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. After joining MindMed as Chief Development Officer in January 2021, he was named CEO in June 2021.

Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in CNS conditions such as multiple sclerosis, Alzheimer’s Disease and Parkinson’s Disease.

Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

Miri Halperin Wernli, PhD
Executive President and Board Director

Dr. Halperin Wernli is a senior pharmaceutical and biomedical executive with over 30 years of strategic and operational leadership and a deep understanding of clinical psychiatry and of drug and product development in heavily regulated environments.

Dr. Halperin Wernli was appointed Executive President in February 2021 and has served on our Board of Directors since August 2020. Prior to joining MindMed, Dr. Halperin Wernli co-founded Creso Pharma, a cannabis company, and listed the company on the Australian Stock exchange (ASX) in October 2016. She was the Group CEO and Executive Director of the Board until August 2020.

Prior to founding Creso Pharma, Dr. Halperin Wernli worked in clinical psychiatry in Swiss academic hospital settings. She later held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Her extensive pharmaceutical industry and biomedical research and development experience covers the full spectrum from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several therapeutic areas.

Dr. Halperin Wernli is a skilled clinician in child and adult psychiatry and an experienced Pharmaceutical leader with skills and broad expertise in Drug Development, Regulatory Affairs, Project & Portfolio Management, Development Finance & Controlling, and Corporate Strategy and Governance.

Cynthia Hu, JD
Chief Legal Officer & Corporate Secretary

Cynthia joined MindMed in December 2021 as Chief Legal Officer and Corporate Secretary. Previously, from 2009-2021, she served as COO, General Counsel & Secretary at CASI Pharmaceuticals, Inc. and, from 2006 to 2009, as VP, General Counsel, of its predecessor, EntreMed, Inc. Prior to that, she served as senior associate for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate and financing matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, Ms. Hu was counsel for a NYSE-listed financial institution and prior to that was in private law practice at Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on corporate transactions and compliance with corporate and securities laws.

Daniel R. Karlin, MD MA
Chief Medical Officer

Dan joined MindMed as Chief Medical Officer in February 2021 following MindMed’s acquisition of HealthMode, the company he co-founded and led as CEO.

Prior to HealthMode, he built and led clinical, informatics, and regulatory strategy for Pfizer’s Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. He previously served as founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to several pharmaceutical, biotech, and health technology companies. He is also a founding Advisor to the Digital Biomarkers Journal, founder and Board Member, Digital Medicine Society (DiMe), and is on committee Leadership Digital Drug Development Tools at Critical Path Alzheimer’s Disease, MJFF, and Mental Health IT at the APA.

Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is an Assistant Professor of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.

Dave Guebert
Chief Financial Officer

Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations. He went on to serve as the Controller for the XV Olympic Winter Games from 1986 to 1988. Since then has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry. He currently sits as a board member and Audit Committee Chair for Legend Power Systems (TSXV: LPS), RMMI Inc. (CSE: RMMI) and Quisitive Technology Solutions, Inc. (TSXV: QUIS). From 2010 to 2017, he was board member and Audit Committee Chair of Merus Labs International Inc. (TSX: MSL; NSDQ: MSLI), a specialty pharmaceutical company.

Dave is a graduate of the University of Saskatchewan. He has served as a volunteer on the Audit and Finance Committee of the Calgary Stampede and the Board of the Calgary Olympic Development Association as well as various roles in hockey, baseball and his community.

Carrie Liao, CPA
VP, Corporate Controller & Accounting Principal

Carrie Liao, CPA is an active Certified Public Accountant in the state of California with over 20 years of accounting and finance leadership experience in public and private companies. Starting at Deloitte, her career has focused on the life science industry from early development through commercialization and manufacturing. Recently, she has successfully supported multiple Initial Public Offering filings. She specializes in Sarbanes-Oxley Act compliance, resolution of complex accounting issues, process improvement, and U.S. Securities and Exchange Commission interim and annual filings.